Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 2/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309877 | 0.87 | EGFR (0.49) | ALKALDH1A1CASP6GFER | |
| SCHEMBL11333631 | 0.86 | NPC1 (0.45) | SHMT2ALKMEN1ALDH1A1KMT2A | |
| SCHEMBL519637 | 0.85 | NPC1 (0.42) | ALKMEN1ALDH1A1KMT2AHRH3 | |
| SCHEMBL519768 | 0.84 | NPC1 (0.49) | PDE7AALKALDH1A1 | |
| SCHEMBL519864 | 0.84 | ALDH1A1 (0.58) | SHMT2PDE7AALKMEN1ALDH1A1 | |
| SCHEMBL520758 | 0.83 | SIGMAR1 (0.54) | MEN1ALDH1A1HPGDKMT2AHRH3 | |
| SCHEMBL521060 | 0.82 | CHEK1 (0.44) | ALKMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL521798 | 0.82 | MEN1 (0.41) | MEN1ALDH1A1KMT2A | |
| SCHEMBL2730690 | 0.82 | CASP6 (0.54) | PDE7AALKALDH1A1CASP6GFER | |
| SCHEMBL2205957 | 0.81 | CASP6 (0.59) | ALKMEN1KMT2ACASP6GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SHMT2 2447/4885PDE7A 4294/4885ALK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.